Comparison of Drug-Eluting Stent and Bare Metal Stent in Reducing Adverse Cardiac Event after Coronary Stenting in Hemodialysis Patients.
- 作者:
Jang Han LEE
1
;
Hyun Woo KIM
;
Mi Hyen YU
;
Jai Won CHANG
;
Won Seok YANG
;
Soon Bae KIM
;
Su Kil PARK
;
Sang Koo LEE
作者信息
1. Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. jspark@amc.seoul.kr
- 出版类型:Original Article
- 关键字:
Drug-eluting stent;
Hemodialysis;
Coronary artery disease
- 医学主题词:
Coronary Artery Disease;
Coronary Vessels;
Drug-Eluting Stents;
Humans;
Incidence;
Myocardial Infarction;
Percutaneous Coronary Intervention;
Renal Dialysis;
Stents;
Stroke
- 来源:Korean Journal of Nephrology
2010;29(1):73-81
- 国家Republic of Korea
- 语言:English
-
摘要:
PURPOSE: The patients treated with hemodialysis have been known to have a high 1-year mortality rate after percutaneous coronary intervention (PCI). We evaluated the clinical benefits of drug-eluting stent (DES), compared to bare-metal stent (BMS) in Korean hemodialysis patients. METHODS: We studied 72 hemodialysis patients (M:F=49:23, age 60+/-11 years) treated with percutaneous coronary intervention (PCI) from January, 1999 to February, 2006. Forty four patients (M:F=28: 16, age 60+/-11 years) treated with DES and 28 patients (M:F=21:7, age 60+/-12 years) with BMS were enrolled. A composite of major adverse cardiac and cerebral endpoints (MACCE) was defined as all-cause death, myocardial infarction, stroke, and target-vessel revascularization (TVR). We compared the incidence of MACCE between DES and BMS group. RESULTS: A composite of MACCE occurred in none in DES group (n=44) and 4 in BMS group (n=28) within 3 months after coronary stenting (Kaplan-Meier survival analysis: 0% vs 14%, respectively, p= 0.02). After 3 months, there was no difference in the incidence of primary end points between two groups. Multi-vessel disease (OR 2.47, 95% CI 1.02-6.11, p<0.05) was associated with a significant increase in the incidence of MACCE within 18 months after coronary artery stenting CONCLUSION: DES may be superior to BMS in reducing adverse cardiac outcome at early period after coronary stenting in HD patients. However, this study showed no significant difference with the lapse of time.
